4.67
0.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About China Resources Pharmaceutical Group
Its shares trade on HKEX under the ticker 3320.HK. It has been listed since 28 October 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥349.37bn and net income of CN¥5.24bn. At that date it held total assets of CN¥370.71bn and shareholders' equity of CN¥66.68bn.
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The company employs 71,000 full-time employees The company went IPO on 2016-10-28. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 28 Oct 2016
- Employees
- 71,000
- Website
- crpharm.com ↗
Leadership
Pay as last reported
- Mr. Xiaosong BaiExecutive Chairman of the Board, since 2022CN¥3.1m
- Mr. Jie ChengPresident, Executive Director, since 2022
- Mme. Ronghui DengChief Financial Officer, since 2023CN¥1.7m
- Mr. Weiquan LiuChairman of Jiangzhong Pharmaceutical
- Mr. Wenchao LuChairman of CR Double-Crane
- Mr. Huawei QiuChairman of CR Sanjiu, since 2019HK$578,000
- Mr. Jianjun WuChairman of CR Pharmaceutical Commercial
- Mr. Wenduo WuDirector and President of CR Sanjiu, Chairman of KPC Pharmaceuticals Inc
- Mr. Xingpin CuiVice President
- Mr. Kai QiuVice President
- Mr. Changan LiuExecutive Director, since 2023
- Mr. Yipeng LiuSecretary of the Discipline Inspection Commission
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 99
- Social
- 99
- Governance
- 46
- Direct emissions (scope 1)
- 170,536.14 t
- Energy emissions (scope 2)
- 555,112.18 t
- Women in the workforce
- 49.83%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- China Resources Pharmaceutical Group employs 71,000 employees in healthcare operations.
- Pharmaceutical Manufacturing segment focuses on R&D and production of healthcare products.
- Pharmaceutical Distribution segment serves hospitals and medical institutions across China.
Weaknesses
- Pharmaceutical Retail segment operates only in China and Hong Kong regions.
- Pharmaceutical Distribution segment relies on hospital and medical institution clients.
- Pharmaceutical Manufacturing segment faces competition from global pharmaceutical firms.
Opportunities
- Expanding Pharmaceutical Distribution segment to new regions in Asia.
- Growing demand for healthcare products in China's aging population.
- Increasing retail pharmacy presence in urban areas of China.
Threats
- Regulatory changes in China's pharmaceutical industry could impact operations.
- Global economic downturn may reduce healthcare spending.
- Competition from international pharmaceutical companies intensifies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.